Etrumadenant (AB928)
Various Solid Tumors
Phase 2Active
Key Facts
About Arcus Biosciences
Founded in 2015, Arcus Biosciences is a clinical-stage biopharma with a mission to develop best-in-class cancer therapies through its proprietary 'Combining to Cure®' philosophy. The company has built a fully integrated platform, advancing a deep pipeline targeting key immuno-oncology pathways like adenosine signaling and TIGIT. With strategic partnerships, including a major collaboration with Gilead Sciences, and multiple programs in late-stage development, Arcus is positioned as a significant player in the next wave of oncology combination treatments.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| Jemperli (dostarlimab) combinations | GSK | Phase 3 |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| Taiho Oncology Pipeline | Otsuka Holdings | Multiple (I-III) |
| Lenvatinib + Pembrolizumab | Eisai | Phase 3 / Marketed |
| PD-1/PD-L1 Inhibitor | PeptiDream | Phase 1 |
| Cadonilimab (AK104) | Akeso | Phase III |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved / Phase 3 |